Prostate-specific membrane antigen (PSMA) PET/CT is a molecular imaging modality that exploits a cell-surface antigen overexpressed on prostate cancer cells to enable more sensitive detection and localization of metastatic disease than conventional anatomic imaging (CT and bone scintigraphy), which rely on size- and density-based detection thresholds rather than a tumor-specific molecular target. The underlying principle is that molecular/functional imaging targeting a disease-specific biomarker can outperform conventional structural imaging in diagnostic accuracy and staging sensitivity, with direct implications for treatment planning prior to curative-intent therapy; this situates the concept within diagnostic/nuclear medicine oncology and the broader theory of biomarker-driven versus anatomy-driven cancer staging.
Prostate-specific membrane antigen (PSMA) PET/CT is a molecular imaging modality that exploits a cell-surface antigen overexpressed on prostate cancer cells to enable more sensitive detection and loc…